CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) recently granted 4,676 restricted stock units to 13 newly hired non-executive employees on Aug. 15 as employment inducements, extending equity compensation to new staff as the biopharmaceutical company develops and commercializes treatments for metabolic dysfunction-associated steatohepatitis.
The awards were issued under Madrigal’s 2025 Inducement Plan and approved by the company’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), which permits certain equity awards to individuals entering employment with a company.
The 13 employees received an aggregate 4,676 time-based restricted stock units. The awards will vest in four equal installments on the first four anniversaries of the grant date, provided each recipient remains employed by Madrigal on the applicable vesting date.
Madrigal, based in Conshohocken, focuses on treatments for metabolic dysfunction-associated steatohepatitis, or MASH, a liver disease.
Its primary commercial drug, Rezdiffra, or resmetirom, is a once-daily oral therapy designed to target underlying causes of MASH. The drug became the first treatment approved by both the U.S. Food and Drug Administration and European Commission for MASH with moderate to advanced fibrosis, classified as stages F2 to F3.
Madrigal is also evaluating Rezdiffra in an ongoing Phase 3 outcomes trial for patients with compensated MASH cirrhosis, classified as F4c.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.